Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track OPK with free AI briefings, catalyst countdowns, and dilution alerts.

OPK · OPKO HEALTH, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$384M Cash on Hand
28.9mo Cash Runway
Follow OPK by email Get an email when OPK reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about OPK, unsubscribe in one click. Privacy

📣 What OPK Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Calcifediol Secondary Hyperparathyroidism Due to Renal Causes Phase 4 · NCT03588884 Completed
Calcifediol Oral Product Secondary Hyperparathyroidism Due to Renal Causes Phase 4 · NCT03588884 Completed
Cholecalciferol Secondary Hyperparathyroidism Due to Renal Causes Phase 4 · NCT03588884 Completed
Bevasiranib Age Related Macular Degeneration Phase 3 · NCT00557791 Withdrawn
Somatrogon Pediatric Growth Hormone Deficiency Phase 3 · NCT02968004 Completed
Modified-release Calcifediol Capsule (CTAP101) Chronic Kidney Disease Phase 3 · NCT02282813 Completed
Cohort 2 Matching Sugar Capsule Chronic Kidney Disease Phase 2/3 · NCT01219855 Completed
Cohort 2 CTAP101 Capsules - 30µg Chronic Kidney Disease Phase 2/3 · NCT01219855 Completed
Cohort 1 Matching Sugar Capsule Chronic Kidney Disease Phase 2/3 · NCT01219855 Completed
Cohort 1 CTAP101 Capsules- 60µg Chronic Kidney Disease Phase 2/3 · NCT01219855 Completed
Cohort 1 CTAP101 Capsules - 90µg Chronic Kidney Disease Phase 2/3 · NCT01219855 Completed
OPK-88006 MASH Phase 1/2 · NCT07512427 Recruiting
OPK-88003 Type 2 Diabetes Mellitus Phase 2 · NCT03406377 Completed
Metformin Diabetes Mellitus, Type 2 Phase 2 · NCT02119819 Completed
MDX2004 Advanced Tumors Phase 1/2 · NCT07110584 Recruiting
MDX2003 Lymphoma Phase 1/2 · NCT07249905 Recruiting

Also used in these trials (approved or third-party drugs, not OPK's own candidates): Paricalcitol, Somatropin, Ranibizumab, Doxercalciferol, Calcitriol, Valproic Acid, Lamotrigine.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

OPK holds $384M in cash and short-term investments (as of Sep 30, 2026) and burns about $39.9M/quarter from operations, an estimated runway of 28.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when OPK files for a raise →

👥 Who Owns OPK

Insiders 35.6% Other 5%+ holders 0.8% Institutions (293 holders) 27.6% Public and other holders 36%
HolderTypeShares% of sharesAs of
Frost Phillip Md Et Al
CEO & Chairman, Director, 10% owner · +500,000 options
Insider 255,429,406 34.40% 2026-06-29
Steven D Rubin
Executive VP-Administration, Director · +437,500 options
Insider 6,571,966 0.89% 2026-07-24
OPKO HEALTH, INC. 5%+ holder (13D) 5,692,916 0.77% 2026-11-04
Subbarao V Uppaluri
Director · +130,000 options
Insider 1,158,817 0.16% 2026-03-18
Adam Logal
Sr. Vice President, CFO · +437,500 options
Insider 563,396 0.08% 2026-07-24
John A Paganelli
Director · +60,000 options
Insider 389,914 0.05% 2026-11-05

Share count 742,506,477 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full OPK picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OPK and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.